Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Conditions
Interventions
Arhalofenate 600 mg
Allopurinol 300 mg
+3 more
Locations
56
United States
Birmingham, Alabama, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
El Cajon, California, United States
Long Beach, California, United States
Start Date
March 1, 2014
Primary Completion Date
January 1, 2015
Completion Date
January 1, 2015
Last Updated
January 29, 2018
NCT07089888
NCT07453004
NCT07504146
NCT07089875
NCT07116746
NCT05109936
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions